Elevated TGF-β1 levels might protect HCV/HIV-coinfected patients from liver fibrosis

European Journal of Clinical Investigation

Volumn 41, Issue 1, 2011, Pages 70-76

  Rallón, Norma I ^a   Barreiro, Pablo ^a   Soriano, Vincent ^a   García Samaniego, Javier ^a   López, Mariola ^a   Benito, José M ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

HCV; HIV; Liver fibrosis; TGF 1; Treg cells

Indexed keywords

ANTIRETROVIRUS AGENT; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; BLOOD; CONTROLLED STUDY; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MIXED INFECTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE;

ADULT; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER CIRRHOSIS; MALE; MIDDLE AGED; TRANSFORMING GROWTH FACTOR BETA1;

EID: 78650048643     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02381.x     Document Type: Article

References (40)

1. Koup R, Safrit J, Cao Y, Andrews CA, McLeod G, Borkowsky W et al. Temporal association of cellular immune responses with the initial control of viremia in primary HIV type 1 syndrome. J Virol 1994;68:4650-5.
2. Thimme R, Oldach D, Chang K, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001;194:1395-406.
3. Benito J, López M, Soriano V. The role of CD8+ T-cell response in HIV infection. AIDS Rev 2004;6:79-88.
4. Ulsenheimer A, Gerlach J, Gruener N, Jung MC, Schirren CA, Schraut W et al. Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. Hepatology 2003;37:1189-98.
5. Kinter A, Hennessey M, Bell A, Kern S, Lin Y, Daucher M et al. CD25(+)CD4(+) regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med 2004;200:331-43.
6. Weiss L, Donkova-Petrini V, Caccavelli L, Balbo M, Carbonneil C, Levy Y. HIV-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood 2004;104:3249-56.
7. Cabrera R, Tu Z, Xu Y, Firpi RJ, Rosen HR, Liu C et al. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004;40:1062-71.
8. Boettler T, Spangenberg H, Neumann-Haefelin C, Panther E, Urbani S, Ferrari C et al. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol 2005;79:7860-7.
9. Liaw Y, Lee C, Tsai S, Liaw BW, Chen TC, Sheen IS et al. T-cell-mediated autologous hepatocytotoxicity in patients with chronic hepatitis C virus infection. Hepatology 1995;22:1368-73.
10. Grüner N, Gerlach T, Jung M, Diepolder HM, Scirren CA, Schraut WW et al. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. J Infect Dis 2000;181:1528-36.
11. Bolacchi F, Sinistro A, Ciaprini C, Demin F, Capozzi M, Carducci FC et al. Increased hepatitis C virus (HCV)-specific CD4+CD25+ regulatory T lymphocytes and reduced HCV-specific CD4+ T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels. Clin Exp Immunol 2006;144:188-96.
12. Ward S, Fox B, Brown P, Worthington J, Fox SB, Chapman RW et al. Quantification and localisation of FOXP3+ T lymphocytes and relation to hepatic inflammation during chronic HCV infection. J Hepatol 2007;47:316-24.
13. Cribier B, Schmitt C, Rey D, Uhl G, Lang JM, Vetter D et al. HIV increases hepatitis C viraemia irrespective of the hepatitis C virus genotype. Res Virol 1997;148:267-71.
14. Dutoit V, Ciuffreda D, Comte D, Gonvers J, Pantaleo G. Differences in HCV-specific T cell responses between chronic HCV infection and HIV/HCV co-infection. Eur J Immunol 2005;35:3493-504.
15. Capa L, Soriano V, García-Samaniego J, Nuñez M, Romero M, Cascajero A et al. Influence of HCV genotype and co-infection with HIV on CD4(+) and CD8(+) T-cell responses to hepatitis C virus. J Med Virol 2007;79:503-10.
16. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A et al. Liver fibrosis progression in HIV and hepatitis C virus coinfected patients. Hepatology 1999;30:1054-8.
17. Bissell D, Roulot D, George J. Transforming growth factor beta and the liver. Hepatology 2001;34:859-67.
18. Border W, Noble N. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-92.
19. Estes J, Wietgrefe S, Schacker T, Southern P, Beilman G, Reilly C et al. Simian immunodeficiency virus-induced lymphatic tissue fibrosis is mediated by transforming growth factor beta 1-positive regulatory T cells and begins in early infection. J Infect Dis 2007;195:551-61.
20. Li M, Wan Y, Sanjabi S, Robertson A, Flavell R. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006;24:99-146.
21. Lin W, Weinberg E, Tai A, Peng LF, Brockman MA, Kim KA et al. HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology 2008;134:803-11.
22. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F et al. Non-invasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48-54.
23. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-50.
24. De Ledinghen V, Douvin C, Kettaneh A, Ziol M, Roulot D, Marcellin P et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006;41:175-9.
25. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003;362:1708-13.
26. Bräu N, Salvatore M, Ríos-Bedoya C, Fernandez-Carbia A, Paronetto F, Rodriguez-Orengo JF et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006;44:47-55.
27. Rallón NI, López M, Soriano V, Garcia-Samaniego J, Romero M, Labarga P et al. Level, phenotype and activation status of CD4+FoxP3+ regulatory T cells in patients chronically infected with HIV and/or hepatitis C virus. Clin Exp Immunol 2009;155:35-43.
28. Pal S, Schnapp L. HIV-infected lymphocytes regulate fibronectin synthesis by TGF beta 1 secretion. J Immunol 2004;172:3189-95.
29. Kekow J, Wachsman W, McCutchan J, Gross WL, Zachariah M, Carson DA et al. Transforming growth factor-beta and suppression of humoral immune responses in HIV infection. J Clin Invest 1991;87:1010-6.
30. Castilla A, Prieto J, Fausto N. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med 1991;324:933-40.
31. Nelson DR, Gonzalez-Peralta RP, Qian K, Xu Y, Marousis CG, Davis GL. Transforming growth factor-beta 1 in chronic hepatitis C. J Viral Hepat 1997;4:29-35.
32. Murawaki Y, Nishimura Y, Ikuta Y, Idobe Y, Kitamura Y, Kawasaki H. Plasma transforming growth factor-beta 1 concentrations in patients with chronic viral hepatitis. J Gastroenterol Hepatol 1998;13:680-4.
33. Kanzler S, Baumann M, Schirmacher P, Dries V, Bayer E, Gerken G et al. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat 2001;8:430-7.
34. Ray S, Broor S, Vaishnav Y, Sarkar C, Girish R, Dar L et al. Transforming growth factor beta in hepatitis C virus infection: in vivo and in vitro findings. J Gastroenterol Hepatol 2003;18:393-403.
35. Flisiak R, Prokopowicz D, Jaroszewicz J, Flisiak I. Plasma transforming growth factor-beta(1) in acute viral hepatitis. Med Sci Monit 2005;11:304-8.
36. Sanvisens A, Serra I, Tural C, Tor J, Ojanguren I, Barluenga E et al. Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection. J Viral Hepat 2009;16:513-8.
37. Flisiak R, Pytel-Krolczuk B, Prokopowicz D. Circulating transforming growth factor beta(1) as an indicator of hepatic function impairment in liver cirrhosis. Cytokine 2000;12:677-81.
38. Bedossa P, Poynard T, Mathurin P, Lemaigre G, Chaput JC. Transforming growth factor beta 1: in situ expression in the liver of patients with chronic hepatitis C treated with alpha interferon. Gut 1993;34:S146-S147.
39. Roulot D, Durand H, Coste T, Rautureau J, Strosberg AD, Benarous R et al. Quantitative analysis of transforming growth factor beta 1 messenger RNA in the liver of patients with chronic hepatitis C: absence of correlation between high levels and severity of disease. Hepatology 1995;21:298-304.
40. Dejaco C, Duftner C, Schirmer M. Are regulatory T-cells linked with aging? Exp Gerontol 2006;41:339-45.